Bipolar disorder. A practical guide to drug treatment

CNS Drugs

Volumn 6, Issue 1, 1996, Pages 35-52

  Bauer, Michael ^a   Ahrens, Bernd ^a  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; BENZODIAZEPINE; CALCIUM ANTAGONIST; CARBAMAZEPINE; CLOZAPINE; FLUPENTIXOL DECANOATE; IMIPRAMINE; LITHIUM; LITHIUM ACETATE; LITHIUM CARBONATE; LITHIUM SULFATE; LORAZEPAM; NEUROLEPTIC AGENT; NIMODIPINE; THYROXINE; VALPROIC ACID; VERAPAMIL;

BLOOD TOXICITY; ELECTROCONVULSIVE THERAPY; GASTROINTESTINAL SYMPTOM; HUMAN; MANIC DEPRESSIVE PSYCHOSIS; NEPHROTOXICITY; NEUROTOXICITY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PSYCHOTHERAPY; REVIEW; SUICIDE;

EID: 0029982805     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-199606010-00004     Document Type: Review

References (126)

1. Goodwin FK, Jamison KR. Manic-depressive illness. New York: Oxford University Press, 1990
2. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994
3. World Health Organization. International classification of diseases. 10th ed. Geneva: World Health Organization, 1992
4. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd ed. Washington, DC: American Psychiatric Association, 1980
5. Dunner DL, Fieve RR. Clinical factors in lithium carbonate prophylaxis failure. Arch Gen Psychiatry 1974; 30: 229-33
6. Angst J, Ernst C. Current concepts of the classification of affective disorders. Int Clin Psychopharmacol 1993; 8: 211-5
7. Grof P, Alda M, Grof E, et al. Lithium response and genetics of affective disorders. J Affect Dis 1994; 35: 85-95
8. Post RM. The transduction of psychosocial stress into the neurobiology of recurrent affective disorder. Am J Psychiatry 1992; 149: 999-1010
9. Angst J. The course of affective disorders. Psychopathology 1986; 19 Suppl. 2: 47-52
10. Schou M, Juel-Nielsen N, Strömgren E, et al. The treatment of manic psychoses by administration of lithium salts. J Neurol Neurosurg Psychiatry 1954; 12: 250-60
11. Baastrup PC, Schou M. Lithium as a prophylactic agent: its effect against recurrent depressions and manic-depressive psychosis. Arch Gen Psychiatry 1967; 16: 162-72
12. Sheard MH, Marini JL, Bridges CI, et al. The effect of lithium on impulsive aggressive behavior in man. Am J Psychiatry 1976; 133: 1409-13
13. Campbell M, Small AM, Green WH, et al. Behavioral efficacy of haloperidol and lithium carbonate. Arch Gen Psychiatry 1984; 41: 650-6
14. Müller-Oerlinghausen B, Ahrens B, Grof E, et al. The effect of long-term lithium treatment on the mortality of patients with manic-depressive and schizoaffective illness. Acta Psychiatr Scand 1992; 86: 218-22
15. Crundwell JK. Lithium and its potential benefit in reducing increased mortality rates due to suicide. Lithium 1994; 5: 193-204
16. Ahrens B, Müller-Oerlinghausen B, Schou M, et al. Excess cardiovascular and suicide mortality of affective disorders may be reduced by lithium-prophylaxis. J Affect Disord 1995; 33: 67-75
17. Gelenberg AJ, Kane JM, Keller MB, et al. Comparison of standard and low serum levels of lithium for maintenance treatment of bipolar disorders. N Engl J Med 1989; 321: 1489-93
18. Schou M. Relapse prevention in manic-depressive illness: important and unimportant factors. Can J Psychiatry 1991; 36: 502-6
19. Foster JR. Use of lithium in elderly psychiatric patients: a review of the literature. Lithium 1992; 3: 77-93
20. Bell AJ, Cole A, Eccleston D, et al. Lithium neurotoxicity at normal therapeutic levels. Br J Psychiatry 1993; 162: 689-92
21. Heim W, Oelschläger H, Kreuter J, et al. Liberation of lithium from sustained release preparations. Pharmacopsychiatry 1994; 1: 27-31
22. Plenge P, Mellerup ET, Bolwig TG, et al. Lithium treatment: does the kidney prefer one daily dose instead of two? Acta Psychiatr Scand 1982; 66: 121-8
23. Abraham G, Delva N, Waldron J, et al. Lithium treatment: a comparison of once- and twice-daily dosing. Acta Psychiatr Scand 1992; 85: 65-9
24. Hestbech J, Hansen HE, Amdisen A, et al. Chronic renal lesions following long-term treatment with lithium. Kidney Int 1977; 12: 205-13
25. Gitlin MJ. Lithium-induced renal insufficiency. J Clin Psychopharmacol 1993; 13: 276-9
26. Schou M. Lithium treatment of manic-depressive illness: a practical guide. 5th ed. New York: S Karger, 1993
27. Schou M. Long-lasting neurological sequelae after lithium intoxication. Acta Psychiatr Scand 1984; 70: 594-602
28. Amdisen A. Clinical features and management of lithium poisoning. Med Toxicol 1988; 3: 18-32
29. Jaeger A, Sauder P, Kopferschmitt J, et al. When should dialysis be performed in lithium poisoning? A kinetic study in 14 cases of lithium poisoning. Clin Toxicol 1993; 31 (3): 429-47
30. Post RM, Uhde TW, Ballenger JC, et al. Prophylactic efficacy of carbamazepine in manic-depressive illness. Am J Psychiatry 1983; 140: 1602-4
31. Kishimoto A, Ogura C, Hazama H, et al. Long-term prophylactic effects of carbamazepine in affective disorder. Br J Psychiatry 1983; 143: 327-31
32. Okuma T, Inanaga K, Otsuki S, et al. A preliminary double-blind study on the efficacy of carbamazepine in prophylaxis of manic-depressive illness. Psychopharmacology (Berl) 1981; 73: 95-6
33. Placidi GF, Lenzi A, Lazzerini F, et al. The comparative efficacy and safety of carbamazepine vs lithium: a randomized, double-blind, 3 year trial in 83 patients. J Clin Psychiatry 1986; 47: 490-4
34. Watkins SE, Callender K, Thomas DR, et al. The effect of carbamazepine and lithium on remission from affective illness. Br J Psychiatry 1987; 150: 180-2
35. Lusznat RM, Murphy DP, Nunn CMH. Carbamazepine vs lithium in the treatment of prophylaxis of mania. Br J Psychiatry 1988; 153: 198-204
36. Coxhead N, Silverstone T, Cookson J. Carbamazepine versus lithium in the prophylaxis of bipolar affective disorder. Acta Psychiatr Scand 1992; 85: 114-8
37. Greil W, Ludwig-Mayerhofer W, Czernik A, et al. Lithium - oder Carbamazepinprophylaxe bei affektiven Psychosen? Ergebnisse einer kontrollierten, multizentrischen Studie. In: Müller-Oerlinghausen B, Berghöfer A, editors. Ziele und Ergebnisse der medikamentösen Prophylaxe affektiver Psychosen. Stuttgart, New York: Thieme Verlag, 1994: 113-9
38. Thies-Flechtner K, Seibert W, Walther A, et al. Suizide bei rezidivprophylaktisch behandelten Patienten mit affektiven Psychosen. In: Müller-Oerlinghausen B, Berghöfer A, editors. Ziele und Ergebnisse der medikamentösen Prophylaxe affektiver Psychosen. Stuttgart, New York: Thieme Verlag, 1994: 61-4
39. McElroy SL, Keck Jr PE, Pope Jr HG, et al. Valproate in psychiatric disorders: literature review and clinical guidelines. J Clin Psychiatry 1989; 50 (3 Suppl.): 23-9
40. Calabrese JR, Delucchi GA. Spectrum of efficacy of valproate in 55 patients with rapid-cycling bipolar disorder. Am J Psychiatry 1990; 147: 431-4
41. Nurnberg HG, Martin GA, Karajgi BM, et al. Response to anticonvulsant substitution among refractory bipolar manic patients. J Clin Psychopharmacol 1994; 14: 207-8
42. Emrich GN, Dose M, von Zerssen D. The use of sodium valproate, carbamazepine and oxcarbamazepine in patients with affective disorders. J Affect Disord 1985; 8: 243-50
43. Pope Jr HG, McElroy SL, Keck PE, et al. Valproate in the treatment of acute mania: a placebo controlled study. Arch Gen Psychiatry 1991; 48: 62-8
44. Lipinski Jr JF, Pope Jr HG. Possible synergistic action between carbamazepine and lithium carbonate: a report of three cases. Am J Psychiatry 1982; 139: 948-9
45. Fawcett J, Kravitz HM. The long-term management of bipolar disorders with lithium, carbamazepine, and antidepressants. J Clin Psychiatry 1985; 46: 58-60
46. Strömgren LS. The combination of lithium and carbamazepine in treatment and prevention of manic-depressive disorder: a review and a case report. Compr Psychiatry 1990; 31: 261-5
47. Sharma V, Persad E, Mazmanian D, et al. Treatment of rapid cycling bipolar disorder with combination therapy of valproate and lithium. Can J Psychiatry 1993; 38: 137-9
48. Ketter TA, Pazzaglia PJ, Post RM. Synergy of carbamazepine and valproic acid in affective illness: case report and review of the literature. J Clin Psychopharmacol 1992; 12: 276-81
49. Tohen M, Castillo J, Pope HG, et al. Concomitant use of valproate and carbamazepine in bipolar and schizoaffective disorders. J Clin Psychopharmacol 1994; 14: 67-70
50. Peselow ED, Fieve RR, Difiglia C, et al. Lithium prophylaxis of bipolar illness. The value of combination treatment. Br J Psychiatry 1994; 164: 208-14
51. Prien RF, Gelenberg AJ. Alternatives to lithium for preventive treatment of bipolar disorder. Am J Psychiatry 1989; 146: 840-8
52. Prien RF, Klett CF, Caffey EM. Lithium carbonate and imipramine in prevention of affective episodes. Arch Gen Psychiatry 1973; 29: 420-5
53. Prien RF, Kupfer DJ, Mansky PA, et al. Drug therapy in the prevention of recurrences in unipolar and bipolar affective disorders. Arch Gen Psychiatry 1984; 41: 1096-104
54. Quitkin FM, Kane J, Rifkin A, et al. Prophylactic lithium carbonate with and without imipramine for bipolar 1 patients. Arch Gen Psychiatry 1981; 38: 902-7
55. Ahlfors UG, Baastrup PC, Dencker SJ, et al. Flupenthixol decanoate in recurrent manic depressive illness: a comparison with lithium. Acta Psychiatr Scand 1981; 64: 226-37
56. Esparon J, Kolloori J, Naylor GJ, et al. Comparison of the prophylactic action of flupenthixol with placebo in lithium-treated manic-depressive patients. Br J Psychiatry 1986; 148: 723-5
57. McElroy SL, Dessain EC, Pope Jr HG, et al. Clozapine in the treatment of psychotic mood disorders, schizoaffective disorder, and schizophrenia. J Clin Psychiatry 1991; 52: 411-4
58. Frankenburg FR. Clozapine and bipolar disorder. J Clin Psychopharmacol 1993; 13: 289-99
59. Banov MD, Zarate CA, Tohen M, et al. Clozapine therapy in refractory affective disorders: polarity predicts response in long-term follow-up. J Clin Psychiatry 1994; 55: 295-300
60. Calabrese JR, Meltzer HY, Markovitz PJ. Clozapine prophylaxis in rapid cycling bipolar disorder. J Clin Psychopharmacol 1991; 11: 396-7
61. Suppes T, Phillips KA, Judd CR. Clozapine treatment of nonpsychotic rapid cycling bipolar disorder: a report of three cases. Biol Psychiatry 1994; 36: 338-40
62. Suppes T, Baldessarini RJ, Faedda GL, et al. Risk of recurrence following discontinuation of lithium treatment in bipolar disorder. Arch Gen Psychiatry 1991; 48: 1082-8
63. Stancer H, Persad E. Treatment of intractable rapid cycling manic-depressive disorder with levo-thyroxine. Arch Gen Psychiatry 1982; 39: 311-2
64. Bauer MS, Whybrow PC. Rapid cycling bipolar affective disorder. II. Treatment of refractory rapid cycling with high-dose levothyroxine: a preliminary study. Arch Gen Psychiatry 1990; 47: 435-40
65. Baumgartner A, Bauer M, Hellweg R. Treatment of intractable non-rapid cycling bipolar affective disorder with high-dose thyroxine: an open clinical trial. Neuropsychopharmacology 1994; 10: 183-9
66. Whybrow P. The therapeutic use of triiodothyronine and high dose thyroxine in psychiatric disorder. Acta Med Austriaca 1994; 21: 44-7
67. Goodwin FK, Murphy DL, Bunney Jr WF. Lithium carbonate treatment in depression and mania: a longitudinal double-blind study. Arch Gen Psychiatry 1969; 21: 486-96
68. Stokes PE, Shamoian CA, Stoll PM, et al. Efficacy of lithium as acute treatment of manic-depressive illness. Lancet 1971; I: 1319-25
69. Stokes PE, Kocsis JH, Arcuni OJ. Relationship of lithium chloride dose to treatment response in acute mania. Arch Gen Psychiatry 1976; 33: 1080-4
70. Small JG. Anticonvulsants in affective disorders. Psychopharmacol Bull 1990; 26: 25-36
71. Chou JCY. Recent advances in treatment of acute mania. J Clin Psychopharmacol 1991; 11: 3-21
72. Keck Jr PE, McElroy SL, Tugrul KC, et al. Valproate oral loading in the treatment of acute mania. J Clin Psychiatry 1993; 54: 305-8
73. Bowden CL, Brugger AM, Swann AC, et al. Efficacy of divalproex vs lithium and placebo in the treatment of mania. The Depakote Mania Study Group. JAMA 1994; 271: 918-24
74. Freeman TW, Clothier JL, Pazzaglia P, et al. A double-blind comparison of valproate and lithium in the treatment of acute mania. Am J Psychiatry 1992; 149: 108-11
75. Prien RF, Caffey EM, Klett CJ. A comparison of lithium carbonate and chlorpromazine in the treatment of acute mania Arch Gen Psychiatry 1972; 26: 146-53
76. Shopsin B, Gershon S, Thompson H, et al. Psychoactive drugs in mania. A controlled comparison of lithium carbonate, chlorpromazine, and haloperidol. Arch Gen Psychiatry 1975; 32: 34-42
77. Kane JM. The role of neuroleptics in manic-depressive illness. J Clin Psychiatry 1988; 49: 12-3
78. Mukherjee S, Rosen AM, Caracci G, et al. Persistent tardive dyskinesia in bipolar patients. Arch Gen Psychiatry 1986; 43: 342-6
79. Hollister LE, Müller-Oerlinghausen B, Rickels K, et al. Clinical uses of benzodiazepines. J Clin Psychopharmacol 1993; 13 (4 Suppl.): 1-169
80. Sachs GS, Weiburg JB, Rosenbaum JF. Clonazepam vs neuroleptics as adjuncts to lithium maintenance. Psychopharmacol Bull 1990; 26: 137-43
81. Lenox RH, Newhouse PA, Creelman WL, et al. Adjunctive treatment of manic agitation with lorazepam versus haloperidol: a double-blind study. J Clin Psychiatry 1992; 53: 47-52
82. Bradwejn J, Shirqui C, Koszycki D, et al. Double-blind comparison of the effects of clonazepam and lorazepam in acute mania. J Clin Psychopharmacol 1990; 10: 403-8
83. Chouinard G, Annable L, Turnier L, et al. A double-blind randomized clinical trial of rapid tranquilization with I.M. clonazepam and I.M. haloperidol in agitated psychotic patients with manic symptoms. Can J Psychiatry 1993; 38 Suppl. 4: 114-21
84. Lerer B, Moore M, Meyendorff E. Carbamazepine versus lithium in mania: a double-blind study. J Clin Psychiatry 1987; 48: 89-93
85. Small JG, Klapper MH, Milstein V, et al. Carbamazepine compared with lithium in the treatment of mania. Arch Gen Psychiatry 1991; 48: 915-21
86. Giannini AJ, Houser WL, Loiselle RH, et al. Antimanic effects of verapamil. Am J Psychiatry 1984; 141: 1602-3
87. Dubovsky SL, Franks RD, Lifschitz M, et al. Effectiveness of verapamil in the treatment of a manic patient. Am J Psychiatry 1982; 139: 502-4
88. Garza-Trevino ES, Overall JE, Hollister LE. Verapamil versus lithium in acute mania. Am J Psychiatry 1992; 149: 121-2
89. Janicak PG, Pandey GN, Sharma RP, et al. Verapamil for acute mania: preliminary results from a double-blind, placebo-controlled study [abstract]. Neuropsychopharmacology 1994; 10 (Suppl. 2 Pt 2): 188S
90. Pazzaglia PJ, Post RM, Ketter TA, et al. Preliminary controlled trial of nimodipine in ultra-rapid cycling affective dysregulation. Psychiatry Res 1993; 49: 257-72
91. Goodnick PJ. Nimodipine treatment of rapid cycling bipolar disorder [abstract]. J Clin Psychiatry 1995; 56: 330
92. Black DW, Winokur G, Nasrallah A. Treatment of mania: a naturalistic study of electroconvulsive therapy versus lithium in 438 patients. J Clin Psychiatry 1987; 48: 132-9
93. Mukherjee S, Sackeim HA, Schnurr DB. Electroconvulsive therapy of acute manic episodes: a review. Am J Psychiatry 1994; 151: 169-76
94. Small JG, Klapper MH, Kellams JJ, et al. Electroconvulsive treatment compared with lithium in the management of manic states. Arch Gen Psychiatry 1988; 45: 727-32
95. American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder. Am J Psychiatry Dec 1994; 151 Suppl.: 1-36
96. Zornberg GL, Pope Jr HG. Treatment of depression in bipolar disorder new directions for research. J Clin Psychopharmacol 1993; 13: 397-408
97. Wehr TA, Goodwill FK. Rapid cycling in manic-depressives induced by tricyclic antidepressants. Arch Gen Psychiatry 1979; 36: 555-9
98. Wehr T, Sack D, Rosenthal N, et al. Rapid cycling affective disorder: contributing factors and treatment responses in 51 patients. Am J Psychiatry 1988; 145: 179-84
99. Hurowitz GI, Liebowitz MR. Antidepressant-induced rapid cycling: six case reports. J Clin Psychopharmacol 1993; 13: 52-6
100. Sachs GS, Lafer B, Stoll AL, et al. A double-blind trial of bupropion versus desipramine for bipolar depression. J Clin Psychiatry 1994; 55: 391-3
101. American Psychiatric Association. Practice guideline for major depressive disorder in adults. Am J Psychiatry 1993 Apr; 150 Suppl.: 1-26
102. Baumhackl U, Biziere K, Fischbach R, et al. Efficacy and tolerability of moclobemide compared with imipramine in depressive disorder (DSM-III): an Austrian double-blind, multicentre study. Br J Psychiatry 1989 Oct; 155 Suppl.: 78-83
103. Cohn JB, Collins G, Ashbrook E, et al. A comparison of fluoxetine, imipramine and placebo in patients with bipolar depressive disorder. Int Clin Psychopharmacol 1989; 4: 313-22
104. Himmelhoch JM, Thase ME, Mallinger AG, et al. Tranylcypromine versus imipramine in anergic bipolar depression. Am J Psychiatry 1991; 148: 910-6
105. Ballenger JC, Post RM. Carbamazepine in manic-depressive illness: a new treatment. Am J Psychiatry 1980; 137: 782-90
106. Bauer MS, Whybrow PC. Rapid cycling bipolar disorder: clinical features, treatment, and etiology. In: Amsterdam JD, editor. Advances in neuropsychiatry and psychopharmacology. Vol. 2: Refractory depression. New York: Raven Press, 1991: 191-208
107. Crane GE. The psychiatric side effects of iproniazid. Am J Psychiatry 1956; 112: 494-501
108. Roy-Byrne P, Joffe R, Uhde T, et al. Approaches to the evaluation and treatment of rapid-cycling affective illness. Br J Psychiatry 1984; 145: 543-50
109. Kukopulos A, Reginalid D, Laddomada P, et al. Course of the manic depressive cycle and changes caused by treatments. Pharmacopsychiatry 1980; 13: 156-67
110. Okuma T. Effects of carbamazepine and lithium on affective disorders. Neuropsychobiology 1993; 27: 138-45
111. Sharma V, Persad E. Pharmacotherapy of rapid cycling bipolar disorder: a review. Lithium 1994; 5: 117-25
112. Joyce PR. Carbamazepine in rapid cycling bipolar affective disorder. Int Clin Psychopharmacol 1988; 3: 123-9
113. Grof P, Ahrens B, Yamamotova A, et al. Chronobiologische Verlaufsmuster affektiver Erkrankungen. In: Müller-Oerlinghausen B, Berghöfer A, editors. Ziele und Ergebnisse der medikamentösen Prophylaxe affektiver Psychosen. Stuttgart, New York: Thieme Verlag, 1994: 67-78
114. Cohen LS, Friedman JM, Jefferson JW, et al. A reevaluation of risk of in utero exposure to lithium. JAMA 1994; 271: 146-50
115. Omtzigt JGC, Los FJ, Grobbee DE, et al. The risk of spina bifida aperta after first-trimester exposure to valproate in a prenatal cohort. Neurology 1992; 42 Suppl. 5: 119-25
116. Källen AJB. Maternal carbamazepine and infant spina bifida. Reprod Toxicol 1994; 8: 203-5
117. Waters CH, Belai Y, Gott PS, et al. Outcomes of pregnancy associated with antiepileptic drugs. Arch Neurol 1994; 51: 250-3
118. Perris C. The distinction between bipolar and unipolar affective disorders. In: Paykel ES, editor. Handbook of affective disorders. New York: Guilford, 1982: 45-58
119. Birch NJ, Grof P, Hullin RP, et al. Lithium prophylaxis: proposed guidelines for good clinical practice. Lithium 1993; 4: 225-30
120. Maj M, Pirozzi R, Kemali D. Long-term outcome of lithium prophylaxis in patients initially classified as complete responders. Psychopharmacology (Berl) 1989; 98: 535-8
121. Post RM, Leverich GS, Pazzaglia PJ, et al. Lithium tolerance and discontinuation as pathways to refractoriness. In: Birch NJ, Padgham C, Hughes MS, editors. Lithium in medicine and biology. Carnforth: Mareius Press, 1993: 71-84
122. Bauer M. Refractoriness induced by lithium discontinuation despite adequate serum lithium levels [letter]. Am J Psychiatry 1994; 151: 1522
123. Vestergaard P. Compliance bei Langzeitmedikation mit Lithium: Ein Hauptfaktor erfolgreicher Prophylaxe bei manischdepressiver Erkrankung. In: Müller-Oerlinghausen B, Berghöfer A, editors. Ziele und Ergebnisse der medikamentösen Prophylaxe affektiver Psychosen. Stuttgart, New York: Thieme Verlag, 1994: 61-4
124. Schou M. Artistic productivity and lithium prophylaxis in manic-depressive illness. Br J Psychiatry 1979; 135: 97-103
125. Schumann C, Lenz G, Müller-Oerlinghausen B, et al. Drop-out study in patients of the lithium-out-patient clinic [abstract]. Neuropsychopharmacology 1994; 10 Suppl. 2 Pt 2: 136S
126. Aagaard J, Vestergaard P. Predictors of outcome in prophylactic lithium treatment. A 2-year prospective study. J Affect Disord 1990; 18: 259-66